



NATIONAL LUNG CANCER ROUNDTABLE

4TH ANNUAL MEETING DECEMBER 7-8, 2020

Ella A. Kazerooni, MD, MS, FACR, FSABI, FCCP
Chair, National Lung Cancer Roundtable
Professor of Radiology & Pulmonary Medicine
University of Michigan

Welcome New NLCRT Members!

- American Association for Women in Radiology
- American Lung Cancer Screening Initiative
- Anne Arundel Medical Center
- Baptist Cancer Center
- Beaumont Health System
- Catch It In Time
- EGFR Resisters
- Houston Methodist
- Mount Sinai Health System
- NYU Langone Health Perlmutter Cancer Center
- ROS1ders
- Sanofi
- Society for Public Health Education
- UCSF Helen Diller Family Comprehensive Cancer Center

National Lung Cancer Roundtable

- **Launched in March 2017**
- A national coalition of organizations & invited individuals dedicated to reducing the incidence and mortality from lung cancer in the U.S., ***through coordinated leadership, strategic planning, advocacy, action and collaboration.***
- **Goal:** Stimulate multidisciplinary collaborations that drive actions to reduce lung cancer mortality through risk reduction, early detection, and the assurance of optimal diagnosis and therapy.



Roundtables: Established Plan for Fighting Cancer

- **ACS Roundtable Model:** An effective and efficient platform that harnesses the collective power and expertise of the entire cancer community.
- **Roundtable Purpose:** To further the mission of its members organizations and to take on challenges that no single organization will take on as its own.



NLCRT Members

Currently 147 member organizations including public, private, voluntary organizations, and invited individuals

Members:

- Professional Societies
- Advocacy Organizations
- Government Agencies
- Cancer Centers/Academic Institutions
- Insurance-related Organizations
- State-based Organizations
- Corporate Associates
- Individual Members

**What the
NLCRT
will not do**

- Duplicate member organization roles
- Compete with member organizations
- Take on positions, projects or advocacy that may be in conflict with member organizations
- We are not a “talking shop”
(“*all talk, no action*”)

What the NLCRT will do

- Catalyze organizational engagement
- Serve as a forum to address challenges that no single organization will take on as its own
- Identify unmet needs (GAPS)
- Stimulate collaborations between leading organizations to address those needs
- Support Task Groups made up of experts to conduct the R&D to carry out key initiatives
- Convene expert workshops
- Follow-up workshop recommendations with action

NLCRT Leadership & Staff



Ella A. Kazerooni, MD, MS
Chair of the National Lung
Cancer Roundtable



Douglas E. Wood, MD
Vice Chair of the National
Lung Cancer Roundtable



Robert A. Smith, PhD
Principal Investigator of the
National Lung Cancer
Roundtable



Lauren Rosenthal, MPH
Director, National Lung Cancer
Roundtable



Kenly Burn
Project Specialist, National Lung Cancer
Roundtable



Dionne Christopher
Program Manager, Cancer Screening
Center & NLCRT

Steering Committee of National Experts

- **Joseph Chin, MD, MS**, Centers for Medicare & Medicaid Services
- **V. Paul Doria-Rose, DVM, PhD**, National Cancer Institute
- **Joelle Thirsk Fathi, DNP, ARNP**, Tobacco Treatment Expert, University of Washington
- **Jill Feldman**, Patient Advocate, Co-Founder EGFR Resisters
- **Laurie Fenton Ambrose**, Founder & CEO, GO₂ Foundation for Lung Cancer
- **Thomas P. Houston, MD**, Family Practice Physician, American Academy of Family Physicians
- **Bruce E. Johnson, MD**, Chief Clinical Research Officer, Dana-Farber Cancer Institute
- **Jane Kim, MD, MPH**, Veterans Health Administration
- **Bryan Loy, MD, MBA**, VP & Corporate Medical Director, Humana
- **Peter J. Mazzone, MD, MPH**, Pulmonologist, Cleveland Clinic
- **Jamie S. Ostroff, PhD**, Behavioral Psychologist, Memorial Sloan Kettering Cancer Center
- **Gerard A. Silvestri, MD, MS**, Pulmonologist, Medical University of South Carolina
- **Jamie L. Studts, PhD**, Behavioral Oncology, University of Colorado
- **Richard Wender, MD**, Family Medicine & Community Health, Univ Pennsylvania

Thank you to our NLCRT Sponsors!

AstraZeneca 

AMGEN[®]



Bristol-Myers Squibb

Genentech

A Member of the Roche Group

SANOFI GENZYME 

Lilly | ONCOLOGY

 NOVARTIS

Additional acknowledgement to Guardant Health and Foundation Medicine



Thank you for being on this journey with us!



NLCRT
NATIONAL LUNG CANCER ROUNDTABLE

To create lung cancer survivors

To lower the impact of lung cancer through risk reduction, early detection & assurance of optimal diagnosis and therapy

*To do so in a patient-centered, evidence-based manner
that's inclusive, diverse, proactive & visionary*

